Skip to main content
Premium Trial:

Request an Annual Quote

FDA Adopts Pharsight Simulation Program for HIV Drug Development

NEW YORK, Feb. 25 (GenomeWeb News) - The US Food and Drug Administration has used a quantitative-based modeling and simulation program designed by Pharsight to help it design an end-of-Phase IIa trial for an anti-HIV drug, Pharsight said today.

 

The relationship between Pharsight and the FDA is partly the result of the agency's EOPIIa program, which is part of the Critical Path Initiative. The program enables the FDA to provide sponsors of clinical trials with input earlier in the drug-development cycle.

 

Pharsight said it believes that quantitative-based modeling and simulation during drug development can increase the productivity and efficiency of the process.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.